NASDAQ: PRME · Life Sciences · 4 alerts · CIK 1894562
Share price
$4.19Close, Nov 16
Market cap
$762M
Shares outstanding
181.92MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Prime Medicine, Inc. filings on SEC EDGAR ↗
Prime Medicine reported a net loss of $130.3 million for the nine months ended September 30, 2026, an improvement from the $155.1 million loss in the prior year period. Total revenue increased to $6.2 million, primarily driven by collaboration revenue from related parties, while total stockholders' equity significantly declined from $120.9 million to $8.4 million during the first nine months of 2026.
Prime Medicine reported Q3 2026 financial results, highlighting the first patient dosed in its Phase 1/2 trial for Wilson disease and FDA clearance for its AATD program. The company also completed a $143.7 million public offering, extending its cash runway through 2027.
Term
Q3 2026
“Prime Medicine continued to make significant progress this quarter, highlighted by dosing the first patient in our Phase 1/2 trial of PM577a for Wilson disease, our first clinical study of an in vivo Prime Editing therapy.”
Allan Reine, M.D., Chief Executive Officer
“Our recent financing strengthens our balance sheet and provides additional resources needed to advance these programs through key clinical milestones. Looking ahead, we expect 2027 to be a meaningful year for the patient communities we hope to treat, with initial clinical data anticipated from both PM577a and PM647 and a planned BLA submission for PM359.”
Prime Medicine, Inc. entered into an underwriting agreement for a public offering of 35,714,286 shares of common stock at $3.50 per share. The company also granted underwriters a 30-day option to purchase up to an additional 5,357,142 shares, bringing the total potential gross proceeds to approximately $143.75 million. Proceeds will be used to advance the company's Wilson disease and alpha-1 antitrypsin deficiency programs and for general corporate purposes.
Prime Medicine filed an updated corporate presentation and provided preliminary financial estimates for the quarter ended September 30, 2026. The company estimated its cash, cash equivalents, and short-term investments at approximately $61.2 million, excluding restricted cash. The presentation outlines the company's strategic pipeline, including upcoming clinical data readouts for PM577a and PM647 expected in 2027.